MA34541B1 - Compositions d'anticorps et procédés d'utilisation - Google Patents

Compositions d'anticorps et procédés d'utilisation

Info

Publication number
MA34541B1
MA34541B1 MA35760A MA35760A MA34541B1 MA 34541 B1 MA34541 B1 MA 34541B1 MA 35760 A MA35760 A MA 35760A MA 35760 A MA35760 A MA 35760A MA 34541 B1 MA34541 B1 MA 34541B1
Authority
MA
Morocco
Prior art keywords
methods
antibody compositions
compositions
antibodies
antibody
Prior art date
Application number
MA35760A
Other languages
English (en)
Inventor
Xiaocheng Chen
Mark S Dennis
Becket L Feierbach
Ashley E Fouts
Isidro Hotzel
Bing Li
Jo-Anne Hongo
Rajesh Vij
Original Assignee
Genentech Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45890018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34541(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Hoffmann La Roche filed Critical Genentech Inc
Publication of MA34541B1 publication Critical patent/MA34541B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des compositions comprenant des anticorps anti-gH et des anticorps anti-complexe I ainsi que des procédés d'utilisation de celles-ci.
MA35760A 2010-09-29 2011-09-29 Compositions d'anticorps et procédés d'utilisation MA34541B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38773510P 2010-09-29 2010-09-29
US38772510P 2010-09-29 2010-09-29
US201161504056P 2011-07-01 2011-07-01
PCT/US2011/054092 WO2012047732A2 (fr) 2010-09-29 2011-09-29 Compositions d'anticorps et procédés d'utilisation

Publications (1)

Publication Number Publication Date
MA34541B1 true MA34541B1 (fr) 2013-09-02

Family

ID=45890018

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35760A MA34541B1 (fr) 2010-09-29 2011-09-29 Compositions d'anticorps et procédés d'utilisation

Country Status (21)

Country Link
US (2) US20120082666A1 (fr)
EP (1) EP2621533A4 (fr)
JP (1) JP2014501491A (fr)
KR (1) KR20130112879A (fr)
CN (2) CN103313727B (fr)
AR (1) AR083214A1 (fr)
AU (1) AU2011312425A1 (fr)
BR (1) BR112013007514A2 (fr)
CA (1) CA2811087A1 (fr)
CL (1) CL2013000868A1 (fr)
CO (1) CO6690799A2 (fr)
CR (1) CR20130133A (fr)
EA (1) EA201390467A1 (fr)
EC (1) ECSP13012536A (fr)
IL (1) IL225389A0 (fr)
MA (1) MA34541B1 (fr)
MX (1) MX2013002960A (fr)
PE (1) PE20140195A1 (fr)
PH (1) PH12013500616A1 (fr)
SG (1) SG188657A1 (fr)
WO (1) WO2012047732A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014024023A2 (pt) * 2012-03-28 2017-07-18 Genentech Inc anticorpos idiotípicos anti-hcmv e usos dos mesmos
WO2014099908A1 (fr) * 2012-12-17 2014-06-26 Genentech, Inc. Méthodes d'inhibition de l'infection virale chez les patient greffés
KR102218494B1 (ko) 2013-03-15 2021-02-19 인트린식 라이프사이언시스, 엘엘씨 항-헵시딘 항체 및 그의 용도
WO2014200898A2 (fr) 2013-06-10 2014-12-18 Merck Sharp & Dohme Corp. Protéines se liant à l'antigène neutralisant le cmv
KR102332302B1 (ko) 2013-09-13 2021-12-01 제넨테크, 인크. 세포주에서 숙주 세포 단백질 및 재조합 폴리펩티드 생성물을 검출 및 정량화하기 위한 조성물 및 방법
SG10201802525QA (en) 2013-09-13 2018-04-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
AU2015321462B2 (en) * 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
WO2017032686A1 (fr) 2015-08-21 2017-03-02 F. Hoffmann-La Roche Ag Procédé de réduction de protéines de cellules hôtes dans la chromatographie d'affinité
GB201607979D0 (en) * 2016-05-06 2016-06-22 Liverpool School Tropical Medicine Monomeric proteins and uses thereof
JP7546485B2 (ja) 2018-10-25 2024-09-06 Ｋｍバイオロジクス株式会社 改変ＣＭＶ ｇＢタンパク質及びこれを含むＣＭＶワクチン
CA3230585A1 (fr) * 2021-09-03 2023-03-09 Domenico Tortorella Anticorps anti-hcmv et leurs fragments de liaison a l'antigene
WO2024229365A1 (fr) * 2023-05-03 2024-11-07 The University Of Chicago Polypeptides de ciblage d'hormone de croissance
CN119269807A (zh) * 2024-11-26 2025-01-07 华润昂德生物药业有限公司 一种基于SPR检测EPO与其受体EpoR的体外结合活性的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08506325A (ja) * 1993-01-28 1996-07-09 サンド ファーマスーティカル コーポレーション サイトメガロウイルスに対するヒトモノクローナル抗体
WO1996006625A1 (fr) * 1994-08-26 1996-03-07 Eli Lilly And Company Anticorps recombines comportant des regions variables permutees avec des regions determinant la complementarite (cdr)
US6875433B2 (en) * 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
WO2006044643A2 (fr) * 2004-10-15 2006-04-27 Seattle Genetics, Inc. Anticorps anti-cd70 et son utilisation pour le traitement et la prevention du cancer et des troubles immunitaires
CA2618796C (fr) * 2005-08-11 2018-01-02 Arpi Matossian-Rogers Peptides pour traitement et diagnostic d'une maladie auto-immune
US20080003605A1 (en) * 2006-05-24 2008-01-03 The University Of Chicago Microarray analysis of light chain variable gene expression and methods of use
EP3031469B1 (fr) * 2006-06-07 2023-08-23 The Trustees Of Princeton University Complexe de protéine de surface du cytomégalovirus destiné à être utilisé dans des vaccins et en tant que cible de médicament
ES2363992T3 (es) * 2006-12-15 2011-08-22 Ribovax Biotechnologies Sa Anticuerpos frente a citomegalovirus humano (cmvh).
US8124093B2 (en) * 2008-07-16 2012-02-28 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof

Also Published As

Publication number Publication date
HK1189501A1 (zh) 2014-06-13
WO2012047732A2 (fr) 2012-04-12
US20150376265A1 (en) 2015-12-31
IL225389A0 (en) 2013-06-27
ECSP13012536A (es) 2013-06-28
WO2012047732A3 (fr) 2013-05-30
PH12013500616A1 (en) 2013-06-03
CR20130133A (es) 2013-08-29
MX2013002960A (es) 2013-05-09
SG188657A1 (en) 2013-05-31
BR112013007514A2 (pt) 2019-09-24
EA201390467A1 (ru) 2013-11-29
EP2621533A2 (fr) 2013-08-07
CN103313727A (zh) 2013-09-18
CN103313727B (zh) 2015-07-22
EP2621533A4 (fr) 2015-06-17
AR083214A1 (es) 2013-02-06
CO6690799A2 (es) 2013-06-17
JP2014501491A (ja) 2014-01-23
CL2013000868A1 (es) 2014-01-24
AU2011312425A1 (en) 2013-04-11
KR20130112879A (ko) 2013-10-14
PE20140195A1 (es) 2014-02-24
CN104945505A (zh) 2015-09-30
CA2811087A1 (fr) 2012-04-12
US20120082666A1 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
MA34541B1 (fr) Compositions d'anticorps et procédés d'utilisation
MA34818B1 (fr) Anticorps anti-pcsk9 et procédés d'utilisation
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
MA34881B1 (fr) Anticorps et immunoconjugués anti-mésothéline
MA35712B1 (fr) Anticorps anti-htra1 et leurs procédés d'utilisation
MA33256B1 (fr) Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
MA34519B1 (fr) Anticorps anti-fap et procédés d'utilisation
MA35898B1 (fr) Anticorps anti-lrp5 et leurs procédés d'utilisation
MA37538A2 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
MA34524B1 (fr) Anticorps pour le récepteur 3 du facteur de croissance épidermique (her3)
MA34722B1 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
MA38632B1 (fr) Anticorps anti-récepteur de transferrine et procédés d'utilisation
MA35009B1 (fr) Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
SG10201914119TA (en) Anti-b7-h3 antibodies and antibody drug conjugates
MA40576A (fr) Anticorps et immunoconjugués anti-her2
MA34488B1 (fr) Composition pesticides
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
MA39095A1 (fr) Anticorps et immunoconjugués anti-cd33
MA47664B1 (fr) Anticorps anti-c10orf54 et leurs utilisations
MA33492B1 (fr) Inhibiteurs de bace
MA33210B1 (fr) Nouveaux anticorps anti-a5b1 et leurs utilisations
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
EP2603237A4 (fr) Compositions d'anticorps anti-hemagglutinine et ses méthodes d'utilisation
MA38273A1 (fr) Thérapie de combinaison avec des anticorps anti-her3
MA38686A1 (fr) Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés